Sugi Predict

Sugi Predict / Compounds / SCHEMBL6498261

SCHEMBL6498261

SCHEMBL6498261

Cc1nc2c(Cl)c(Cn3c(C)nc4ccc(C(=O)O)nc43)ccc2n1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 2/20 0.37
▸ PIK3C2B O00750 2/20 0.36
▸ GLP1R P43220 2/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ DCTPP1 Q9H773 1/20 0.34
▸ HDAC3 O15379 2/20 0.33
▸ HDAC4 P56524 2/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ HDAC7 Q8WUI4 2/20 0.33
▸ HDAC2 Q92769 2/20 0.33
▸ HDAC10 Q969S8 2/20 0.33
▸ HDAC11 Q96DB2 2/20 0.33
▸ HDAC8 Q9BY41 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501139 0.89 KDM4E (0.38) PIK3CBKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL6305366 0.82 PIK3CB (0.41) PIK3CBPIK3C2BGLP1RKMT2AMAPT
SCHEMBL6500315 0.82 DCTPP1 (0.40) PIK3CBPIK3C2BGLP1RKMT2AMAPT
SCHEMBL6498900 0.82 PTGS2 (0.42) KMT2ASMN1; SMN2PPARGNPC1RAB9A
SCHEMBL6495547 0.81 PPARG (0.53) MAPTSMN1; SMN2ALDH1A1PPARGNPC1
SCHEMBL6299043 0.79 PIK3CB (0.51) PIK3CBPIK3C2BKMT2AMAPTSMN1; SMN2
SCHEMBL6492552 0.78 KMT2A (0.38) GLP1RKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL6299786 0.77 ALDH1A1 (0.43) PIK3CBKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL6299335 0.77 PPARG (0.47) GLP1RMAPTSMN1; SMN2ALDH1A1PPARG
SCHEMBL6299802 0.77 SMN1; SMN2 (0.44) GLP1RKMT2AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 — — US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 — — US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 — — US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PIK3CB 1729/4885PIK3C2B 2934/4885GLP1R 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.